Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients

NCT00144300 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00144300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2005
Completion date
Not reported
Enrollment
246 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease